Kynamro achieves significant reduction in MACE

A retrospective analysis has shown that patients treated with Kynamro (mipomersen sodium) injection for a mean of two years had a significant reduction in major adverse cardiovascular events (MACE) compared to two years prior to therapy.

The new two-year data from a Phase III long-term extension study of Kynamro injection were presented at a scientific session at the annual American Heart Association meeting in Chicago, according to the drug’s developers - Genzyme, a Sanofi (Euronext: SAN) subsidiary, and Isis Pharmaceuticals (Nasdaq: ISIS). Kynamro is approved in the USA to reduce low density lipoprotein (LDL)-cholesterol, apoB, total cholesterol and non-HDL cholesterol as an adjunct to lipid lowering medication and diet.

“This analysis is very encouraging as the rate of MACE declined sevenfold after two years of treatment with Kynamro in patients with homozygous and heterozygous familial hypercholesterolemia (FH),” said John Kastelein, professor of medicine, chairman of the department of vascular medicine, Academic Medical Center, University of Amsterdam, adding: “This analysis represents an important finding and supports the potential for further study of the therapeutic benefit of Kynamro in patients.”